MTOR and metabolic dysfunction-associated steatotic liver disease: Dapagliflozin affects hepatic steatosis in NAFLD by downregulating lipogenic enzymes and activating the AMPK-mTOR pathway, while promoting fatty acid oxidation and autophagy to mitigate disease progression.